<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05127395</url>
  </required_header>
  <id_info>
    <org_study_id>007.PHA.2020.A</org_study_id>
    <nct_id>NCT05127395</nct_id>
  </id_info>
  <brief_title>Impact of Dosing Weight on Clinical Outcomes in Obese Patients Receiving Acyclovir for HSV Encephalitis (ID-OPRAH)</brief_title>
  <official_title>Impact of Dosing Weight on Clinical Outcomes in Obese Patients Receiving Acyclovir for HSV Encephalitis (ID-OPRAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Methodist Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Methodist Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter retrospective chart review of patients admitted to any of the six study centers&#xD;
      (SSM Health - St. Clare, St. Mary's, Saint Louis University Hospital, St. Anthony's, St.&#xD;
      Mary's Madison, Rush University Medical Center, or Methodist Dallas Medical Center) between&#xD;
      January 1, 2013 and December 31, 2019 will be conducted. All study centers utilize Epic ®&#xD;
      electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be&#xD;
      extracted from. Each study center will obtain individual IRB approval prior to data&#xD;
      collection. SSM - St. Clare will serve as the lead center for the study with all other&#xD;
      centers sending collected and de-identified data to this central site for analysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Obese - WHO definition: Body Mass Index &gt; 30 kg/m2&#xD;
&#xD;
        -  Ideal Body Weight (IBW) (male) - 50.0 kg + 2.3 kg x (patient height in inches, above 60&#xD;
           inches)&#xD;
&#xD;
        -  Ideal Body Weight (female) - 45.5 kg + 2.3 kg x (patient height inches, above 60 inches)&#xD;
&#xD;
        -  Adjusted Body Weight - IBW + [0.4 x (ABW - IBW)]&#xD;
&#xD;
        -  HSV encephalitis - PCR positive for HSV-1 or HSV-2 in CSF during index admission&#xD;
&#xD;
        -  Baseline Serum Creatinine (S Cr) - The SCr value obtained before the start of acyclovir&#xD;
           therapy on which the dose of acyclovir should be based upon&#xD;
&#xD;
        -  Acute Kidney Injury (AKI) - per RIFLE criteria and while receiving acyclovir: SCr&#xD;
           doubles or urine outpout &lt; 0.5 mL/kg/hr for 12 hours&#xD;
&#xD;
        -  End-stage renal disease (ESRD) on admission - mention of a diagnosis of ESRD in&#xD;
           electronic medical records prior to receipt of acyclovir&#xD;
&#xD;
        -  Guideline-approved, weight-based doses - within 10% of 10 mg/kg dose (to account for&#xD;
           rounding due to vial size)&#xD;
&#xD;
        -  Adequate hydration - IV fluid order (other than KVO [keep vein open]) within 24 hours&#xD;
           before acyclovir start AND either IV fluid order (other than KVO) for majority of&#xD;
           acyclovir course or IV fluid + oral diet for majority of acyclovir course&#xD;
&#xD;
        -  Appropriately renally dose-adjusted doses - Frequency of acyclovir matches package&#xD;
           insert recommendations based on creatinine clearance at baseline&#xD;
&#xD;
        -  Interacting medications - Mycophenolate, probenecid, zidovudine, tenofovir, valproic&#xD;
           acid, phenytoin&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">November 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Over 1 month</time_frame>
    <description>Will assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HSV Encephalitis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>To assess the clinical impact of dosing acyclovir based on IBW or adjBW for HSV encephalitis to definitively guide safe and effective therapy.</intervention_name>
    <description>study center utilize Epic ® electronic health record (Verona, Wisconsin; www.epic.com) for which all data will be extracted from. Each study center will obtain individual IRB approval prior to data collection. SSM - St. Clare will serve as the lead center for the study with all other centers sending collected and de-identified data to this central site for analysis.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  More than one dosing weight strategy utilized for &gt; 24 hours for IV acyclovir dosing&#xD;
             during the index admission&#xD;
&#xD;
          -  Patients transferred to the hospital already on IV acyclovir for HSV encephalitis&#xD;
&#xD;
          -  ESRD on admission&#xD;
&#xD;
          -  Concomitant pathogen causing meningitis or encephalitis&#xD;
&#xD;
          -  Oral acyclovir used for treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients Admitted to a SSM Health - St. Clare (STL), St. Mary's (STL), Saint Louis&#xD;
             University Hospital (STL), St. Anthony's (OKC), St. Mary's Madison (WIS), Rush&#xD;
             University Medical Center (RUMC), or Methodist Dallas Medical Center&#xD;
&#xD;
          -  &gt; 18 years old&#xD;
&#xD;
          -  Positive cerebrospinal fluid (CSF) PCR for HSV-1 or HSV-2&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Received guideline-approved, weight-based doses of IV acyclovir for HSV encephalitis&#xD;
             for at least 72 hours during the index admission&#xD;
&#xD;
          -  Received appropriately renal dose-adjusted doses of IV acyclovir per package insert&#xD;
             recommendations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  More than one dosing weight strategy utilized for &gt; 24 hours for IV acyclovir dosing&#xD;
             during the index admission&#xD;
&#xD;
          -  Patients transferred to the hospital already on IV acyclovir for HSV encephalitis&#xD;
&#xD;
          -  ESRD on admission&#xD;
&#xD;
          -  Concomitant pathogen causing meningitis or encephalitis&#xD;
&#xD;
          -  Oral acyclovir used for treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Crotty, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Dallas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Methodist Charlton Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Herpes Simplex</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

